Top entities: Akeso, Hong Kong Stock Exchange.

What category does this event fall under?

Tech — classified as clinical trial.

What is the sentiment of coverage?

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 10, 2026. Coverage continues to evolve.

Tech clinical trial

Akeso Doses First Patient in AK146D1 Phase II

Q: When did this event occur?

First reported Aug 10, 2026; last updated Aug 10, 2026.

Q: What is the market impact?

General. The announcement is a positive clinical development for Akeso, potentially strengthening its pipeline and competitive position in the ADC and bispecific antibody space.

Analysis based on 6 articles · First reported Aug 10, 2026 · Last updated Aug 10, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The announcement is a positive clinical development for Akeso, potentially strengthening its pipeline and competitive position in the ADC and bispecific antibody space. It may positively influence investor sentiment toward Akeso's stock, though the impact is likely modest given the early-stage nature of the trial.

Biotechnology Pharmaceuticals

Event Summary

Akeso announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab, its PD-1/VEGF bispecific antibody, for the treatment of advanced breast cancer. The study focuses on first-line treatment of HR+/HER2- breast cancer and triple-negative breast cancer (TNBC). This milestone advances Akeso's IO2.0 + ADC2.0 strategy, which combines next-generation immuno-oncology agents with next-generation ADCs to improve efficacy and safety. AK146D1 is designed to address limitations of first-generation ADCs, such as narrow therapeutic window and safety issues. The company is also conducting other combination studies, including a Phase III trial of ivonescimab-based therapy in TNBC and a Phase Ib/II study of AK138D1 with ivonescimab. Akeso has a pipeline of over 50 innovative assets, with 27 in clinical trials and 8 commercial-stage drugs.

Key Actions

80 Akeso dosed first patient

Entities Involved

stock

Akeso

Akeso is the developer and sponsor of the Phase II study, and this milestone advances its IO2.0 + ADC2.0 strategy. The company's pipeline and clinical progress are central to its valuation and growth prospects.

Importance 100.0 Sentiment 40.0

exch

Hong Kong Stock Exchange

Akeso is listed on the Hong Kong Stock Exchange, and the announcement may influence trading activity in its shares, but the exchange itself is not directly affected.

Importance 10.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard